Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. - Wikidata - awgldk - TriplyDB

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q44254904

about

A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Three Case Studies in Making Fair Choices on the Path to Universal Health Coverage.A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort.The economics of treating chronic hepatitis B in Asia.The current economic burden of cirrhosis.The estimation of direct medical costs of treating patients with chronic hepatitis B and C in iran.Health state utilities and quality of life in patients with hepatitis B.Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential?Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension Management of chronic hepatitis B: consensus guidelines Management of hepatitis B in liver transplant recipients.Disease burden of chronic hepatitis B among immigrants in Canada.Direct medical care costs associated with patients diagnosed with chronic HCV.Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.Hepatitis B status in migrants and refugees: increasing health burden in Western Australia.Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey.Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective.Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.Antiviral therapy for various stages of HBV-related diseases: lamivudine and beyond.

P2860

Q28704122-CF88C733-50C1-40BA-8FF9-FB7A4CEE42FD Q33549555-F049937B-7C86-41D8-B2E7-F48CEF6DB4D0 Q33573931-02BC4BB2-6214-4E74-B4B1-49611734E837 Q33804151-05CFF52C-45EC-4202-A1A9-C1CB329EF737 Q33836312-ABFD36B5-57C6-4CEE-9DCE-BE3DCD255FED Q34996644-28FAC52B-5A02-431D-8C8E-D627DB7E8C41 Q35691411-55AADD18-D50D-4AAA-BDA1-35B6483CE8D7 Q35844577-43C084A9-FBDA-437C-ACA9-0C877BB76EC9 Q36091385-19B00308-8B79-4D88-945C-90A92ACCF504 Q36116667-B265F492-1A80-423A-B6FD-F9FE20AF3B9A Q36189795-17BA121A-403C-4D3B-BABF-89026888A49D Q36250930-D16D30C6-5888-4A60-BC97-FB07E7A29B46 Q36379986-A97F84DD-9DA4-4B9A-BDF4-3917D090E134 Q36539020-275BEAEA-2953-4E42-956F-35AD95089888 Q36849343-CCD8E093-F330-4097-8FF1-0C727FB65B35 Q36980721-757FA6B8-8FB1-48ED-976D-AF4EC7B10D05 Q37066397-0FBE9600-0350-49C1-B86C-8D9EF6F723FD Q37078173-E8B6A1C5-B6D6-4995-BF54-73CC991A901C Q38074916-3B8BFA3B-2DBF-49B6-88C2-ED94D202948E Q38655765-8BD66A38-8FC0-44A4-86D8-E179E2A9CBC4 Q39148796-6ADD34B0-552D-4712-A4B9-81BD3C42289F Q39668495-01F5F383-E414-4863-AC36-2F78F465C7D2 Q40400182-9A3677CC-AB26-4D91-86EC-2A4CBCE402F6 Q40679543-5629A885-BCAA-4B1B-8813-69B2ABF23E2F Q40934257-043D5E71-0849-4AE6-8BBC-FB233CB68E13 Q40951867-787B9AFE-6F41-465B-8A12-F464FB0327B7 Q42208578-EA649A27-CB5B-45B3-B915-650FEA3CFC9B Q42236429-8ACD56E9-38E6-4E88-BB2E-CD75AB7E4338 Q42321835-35A2AAAA-8430-4942-BFD8-A0FA50A825A2 Q43095281-698BAA48-D74A-449A-81FF-ED875DDBEF13 Q43471901-3DA6D989-D97B-4CD4-8970-5D6DE5EDF2A5 Q45935801-726C7FE2-761A-4AB9-AADE-34D64C95254E Q46646036-003CD4CF-F5B6-4DA8-B6AA-92C6E664FA78

P2860

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q44254904

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@en

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@nl

type

label

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@en

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@nl

prefLabel

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@en

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@nl

P1433

Q44254904-BFDDE57A-9BD5-4787-90FF-58EF29CDB4D0

P1476

Q44254904-CC57AE4A-4E63-4C05-A46F-A56F9BB89056

P2093

Q44254904-26B295F8-7748-441F-BC77-EDA2D646A827

Q44254904-48D5FCD3-D718-4654-BAEA-1006E8A5A5DB

Q44254904-656FCA03-5C0D-465A-9BE2-87DABCD9A3F1

Q44254904-94007744-6F00-41A7-96BB-2298915754A4

Q44254904-C7898D89-E534-44D6-97CE-A2D494B385C6

Q44254904-CD446B93-9AEC-46FE-AD32-BAF6F3DBC459

Q44254904-EB51580B-A507-49EC-9094-8FC73663743B

P2860

Q44254904-00861ED1-BB5C-4668-9C08-A5CD0D5A0949

Q44254904-06E62DD0-FD9D-4B86-A2C5-1E0F46A23B1C

Q44254904-0DC08A0F-9CB8-4DC4-B98A-064AB4702413

Q44254904-0F4BFD73-AFF5-4FFB-8A84-A7CD99D3B711

Q44254904-123A68C1-55F1-479F-BA0B-FA193047E8CD

Q44254904-1788EFB9-47CB-41F1-8286-D7775D90541A

Q44254904-202EC0CE-EB8A-406D-953F-5AF2F5C715E8

Q44254904-2C1A290D-8FD7-4734-8767-378E735AE409

Q44254904-2C774E64-25A1-41F2-AAD4-709E3CBF5224

Q44254904-2F673453-1ABC-4BA5-A269-807E5207AD77

P304

Q44254904-7634539F-3C8D-46EF-939C-AE6993641754

P31

Q44254904-95F74642-995E-4969-854D-A8D3BE3B60F2

P356

Q44254904-32DF7872-3467-46E8-93D1-926D3B250009

P407

Q44254904-44E0025E-6AC4-44FF-8627-2737BAD5B372

P433

Q44254904-4DBD35AB-F454-41D6-9D08-5BF9DB7AE9A7

P478

Q44254904-0778F7B5-8384-445D-993B-0405BE21C792

P577

Q44254904-3608200B-E810-4A77-BCEB-F3B409EFCD29

P5875

Q44254904-784740F2-420D-4FAC-B6D3-08B1FD15508A

P698

Q44254904-CB95A019-DF9C-4BF3-B4AD-81EBB8D5E097

P921

Q44254904-B3968A46-7A41-4DA7-84BC-3548483804B4

P356

J.1572-0241.2006.00769.X

P1433

The American Journal of Gastroenterology

P1476

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.

@en

P2093

Brennan M R Spiegel

http://www.w3.org/2001/XMLSchema#string

Fasiha Kanwal

http://www.w3.org/2001/XMLSchema#string

Gareth S Dulai

http://www.w3.org/2001/XMLSchema#string

Gary Chen

http://www.w3.org/2001/XMLSchema#string

Ian M Gralnek

http://www.w3.org/2001/XMLSchema#string

Mary Farid

http://www.w3.org/2001/XMLSchema#string

Paul Martin

http://www.w3.org/2001/XMLSchema#string

P2860

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.

P304

2076-2089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2006.00769.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6821546

http://www.w3.org/2001/XMLSchema#string

P698

16968510

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis